2013


To access this material please log in or register

Register Authorize
2013/№7

SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision). Approved at the SEHF Congress on December 7, 2012, at the SEHF Board of Directors meeting on March 31, 2013, and at the RSC Congress on September 25, 2013

Mareev V. Yu. 1 , Ageev F. T. 1 , Arutyunov G. P. 1 , Koroteev A. V. 1, Mareev Yu. V. 3 , Ovchinnikov A. G. 4
Belenkov Yu. N. 2 , Vasyuk Yu. A. 2 , Galyavich A. S. 2, Garganeeva A. A. 2, Gilyarevsky S. R.2 , Glezer M. G.2 , Drapkina O. M. 2 , Koziolova N. A.2 , Kots Ya. I.2, Lopatin Yu. M.2, Gilyarevsky S. R.2, Martynov A. I. (RSMSIM President), Moiseev V. S.2, Revishvili A. Sh.2, Sitnikova M. Yu.2, Skibitsky V. V.2, Sokolov E. I.2, Storozhakov G. I.2, Fomin I. V.2, Chesnikova A. I.2, Shlyakhto E. V. (RSC President)
1 – Writing Committee, Members of SEHF Board of Directors
2 – Expert Committee, Members of SEHF Board of Directors
3 – Section «Electrophysiological methods for treatment of CHF»
4 – Section «Diagnostics of HF»

Expert Reviewer Committee:
Akchurin R. S., Aronov D. M., Arkhipov M. V., Bart B. Ya.,
Belousov Yu. B., Boytsov S. A., Gendlin G. E., Golikov A. P.,
Golitsyn S. P., Gurevich M. A., Danielyan M. O., Dovgalevsky P. Ya., Zadionchenko V. S., Karpov R. S., Karpov Yu. A., Kobalava Zh. D., Kuznetsov V. A., Lazebnik L. B., Nasonov E. L., Nedogoda S. V., Nikitin Yu. P., Oganov R. G., Panchenko E. P., Perepech N. B., Podzolkov V. I., Pozdnyakov Yu. A., Rakov A. L., Ruda M. Ya., Rylova A. K., Simonenko V. B., Sidorenko B. I., Staroverov I. I., Sulimov V. A., Tarlovskaya E. I., Tereshchenko S. N., Fomina I. G., Chazova I. E.

Keywords: diagnostics, treatment, guidelines, CHF

DOI: 10.18087 / rhfj.2013.7.1860

  1. Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005) The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology. Eur Heart J. 2005;26 (22):2472.
  2. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29 (19):2388–2442.
  3. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14 (8):803–869.
  4. ACC/ AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). http://www.acc.org/qualityandscience/clinical/guidelines/failure/update/index. pdf.
  5. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/ AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119 (14):1977–2016.
  6. HFSA 2006 Comprehensive Heart Failure Practice Guideline Journal of Cardiac Failure. 2006;12: e1e122.
  7. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16 (6):e1–194.
  8. Национальные рекомендации по диагностике и лечению ХСН (Утверждены съездом кардиологов РФ в октябре 2003 г.) Журнал Сердечная Недостаточность. 2003;4 (6):276–297.
  9. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная Недостаточность. 2007;8 (1):4–41.
  10. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. И др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (57):1–62.
  11. Беленков Ю. Н., Фомин И. В., Мареев В. Ю. и др. Первые результаты Российского эпидемиологического исследования по ХСН. Журнал Сердечная Недостаточность. 2003;4 (1):26–30.
  12. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4–7.
  13. Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (1): 112–115.
  14. Беленков Ю. Н., Фомин И. В., Мареев В. Ю и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации-данные ЭПОХА–ХСН (часть 2). Журнал Сердечная Недостаточность. 2006;7 (3): 3–7.
  15. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442–463.
  16. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. От имени рабочей группы исследования ЭПОХА–О–ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА–О–ХСН. Журнал Сердечная Недостаточность. 2006;7 (4):164–171.
  17. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355 (3):251–259.
  18. Даниелян М. О. Прогноз и лечение хронической сердечной недостаточности (данные 20-и летнего наблюдения). Автореф. дис. канд. мед. наук. Москва. 2001.
  19. Бадин Ю. В., Фомин И. В. Выживаемость больных ХСН в когортной выборке Нижегородской области (данные 1998–2002 годов.). Всероссийская конференция ОССН: «Сердечная недостаточность, 2005 год» – М., 2005. – с. 31–32.
  20. Фомин И. В. Артериальная гипертония в Российской Федерации – последние 10 лет. Что дальше? Сердце. 2007;6 (3):1–6.
  21. Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность [Агеев Ф. Т. и соавт.] – М.: ГЭОТАР-Медиа, 2010. – c. 7–77.
  22. Щербинина Е. В., Бадин Ю. В., Вайсберг А. Р., и др. Динамика этиологических причин формирования ХСН в репрезентативной выборке Нижегородской области за 9 лет наблюдения (1998–2007 гг.). Всероссийская конференция ОССН: «Сердечная недостаточность, 2007 год» – М., 2007. – с. 38.
  23. Фомин И. В., Бадин Ю. В., Егорова И. С., Щербинина Е. В. Гендерные различия в распространенности сердечно-сосудистых заболеваний (данные когортного исследования репрезентативной выборки Нижегородской области 1998–2002 гг.). Проблемы женского здоровья. 2006;1 (1):37–40.
  24. Hogg K, Swedberg K, McMurray J. Heart Failure with preserved left ventricular systolic function. Epidemiology, Clinical Characteristics, and Prognosis. J Am Coll Cardiol. 2004;43 (3):317–327.
  25. Cowie MR , Fox KF, Wood DA et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002;23 (11):877–885.
  26. McAlister FA, Teo KK, Taher M et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999;138 (1 Pt 1):87–94.
  27. Агеев Ф. Т. Влияние современных медикаментозных средств на течение заболевания «качество жизни» и прогноз больных с различными стадиями хронической сердечной недостаточности. Автореф. Дисс. Докт., Москва, 1997.
  28. Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. The Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Eur J Heart Fail. 1999;1 (2):139–144.
  29. Zile MR , Gaasch WH, Carroll JD et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001;104 (7):779–782.
  30. Fuster V, Ryden LE, Cannom DS et al. ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology / American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27 (16):1979–2030.
  31. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society on Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10 (10):933–989.
  32. Davie AP, Francis CM, Caruana L et al. Assessing diagnosis in heart failure: which features are any use? QJM. 1997;90 (5):335–339.
  33. Mant J, Doust J, Roalfe A et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13 (32):1–207.
  34. Oudejans I, Mosterd A, Bloemen JA et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail. 2011;13 (5):518–527.
  35. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev. 2006;11 (2):95–107.
  36. Kelder JC, Cramer MJ, van Wijngaarden J et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124 (25):2865–2873.
  37. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011;32 (6):670–679.
  38. Paulus WJ, Tschope C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28 (20):2539–2550.
  39. Marwick TH, Raman SV, Carrió I, Bax JJ. Recent developments in heart failure imaging. JACC Cardiovasc Imaging. 2010;3 (4):429–439.
  40. Paterson DI, OMeara E, Chow BJ et al. Recent advances in cardiac imaging for patients with heart failure. Curr Opin Cardiol. 2011;26 (2):132–143.
  41. McMurray J. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362 (3):228–238.
  42. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA. 2011;306 (15):1669–1678.
  43. Dunlay SM, Redfield MM, Weston SA et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009;54 (18):1695–1702.
  44. Khot UN, Jia G, Moliterno DJ et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. JAMA. 2003;290 (16):2174–2181.
  45. Rutten FH, Moons KG, Cramer MJ et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross-sectional diagnostic study. BMJ. 2005;331 (7529):1379.
  46. Hawkins NM, Petrie MC, Jhund PS et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11 (2):130–139.
  47. Daniels LB, Clopton P, Bhalla V et al. How obesity affects the cutpoints for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151 (5):999–1005.
  48. Rudski LG, Lai WW, Afilalo J еt al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23 (7):685–713.
  49. Dokainish H, Nguyen JS, Bobek J et al. Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study. Eur J Echocardiogr. 2011;12 (11):857–864.
  50. Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol. 2007;50 (5):381–396.
  51. Lancellotti P, Moura L, Pierard LA et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11 (4):307–332.
  52. Lancellotti P, Moura L, Pierard LA et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11 (3):223–244.
  53. Popescu BA, Andrade MJ, Badano LP et al. European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. Eur J Echocardiogr. 2009;10 (8):893–905.
  54. Nagueh SF, Bhatt R , Vivo RP et al. Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure. Circ Cardiovasc Imaging. 2011;4 (3):220–227.
  55. Sicari R , Nihoyannopoulos P, Evangelista A et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr. 2008;9 (4):415–437.
  56. Davie AP, Francis CM, Love MP et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312 (7025):222.
  57. Thomas JT, Kelly RF, Thomas SJ et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med. 2002;112 (6):437–445.
  58. Khunti K, Squire I, Abrams KR , Sutton AJ. Accuracy of a 12 lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. Eur J Heart Fail. 2004;6 (5):571–576.
  59. Madias J. Why recording of an electrocardiogram should be required in every inpatient and outpatient encounter of patients with heart failure. Pacing Clin Electrophysiol. 2011;34 (8):963–967.
  60. Schwitter J. Extending the frontiers of cardiac magnetic resonance. Circulation. 2008;118 (2):109–112.
  61. Gebker R , Schwitter J, Fleck E, Nagel E. How we perform myocardial perfusion with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2007;9 (3):539–547.
  62. Beller GA, Heede RC. SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability. J Cardiovasc Transl Res. 2011;4 (4):416–424.
  63. Leong DP, De Pasquale CG, Selvanayagam JB. Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging. JACC Cardiovasc Imaging. 2010;3 (4):409–420.
  64. Myerson S. Valvular and hemodynamic assessment with. Heart Fail Clin. 2009;5 (3):389–400.
  65. Raman SV, Simonetti OP. The CMR examination in heart failure. Heart Fail Clin. 2009;5 (3):283–300.
  66. Sheikine Y, Di Carli MF. Integrated PET / CT in the assessment of etiology and viability in ischemic heart failure. Curr Heart Fail Rep. 2008;5 (3):136–142.
  67. Miller JM, Rochitte CE, Dewey M et al. Diagnostic performance of coronary angiography by 64row CT. N Engl J Med. 2008;359 (22):2324–2336.
  68. Beanlands RS, Nichol G, Huszti E et al. F-18fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50 (20):2002–2012.
  69. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J. 2008;38 (2):101–113.
  70. Doust JA, Glasziou PP, Pietrzak E. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004;164 (18):1978–1984.
  71. Zaphiriou A, Robb S, Murray-Thomas T et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005;7 (4):537–541.
  72. Maisel A, Mueller C, Adams K Jr et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10 (9):824–839.
  73. Fuat A, Murphy JJ, Hungin AP et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006 May;56 (526):327–333.
  74. Yamamoto K, Burnett JC Jr, Bermudez EA et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 2000;6 (3):194–200.
  75. Cowie MR , Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment with patients with possible new heart failure in primary care. Lancet. 1997;350 (9088):1349–1353.
  76. Krishnaswamy P, Lubien E, Clopton P et al. Utility of B-natriuretic pepetide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111 (4):274–279.
  77. Kelder JC, Cowie MR , McDonagh TA et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011;97 (12):959–963.
  78. Kelder JC, Cramer MJ, Verweij WM et al. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail. 2011;17 (9):729–734.
  79. Gustafsson F, Steensgaard-Hansen F, Badskjaer J et al. Diagnostic and prognostic performance of N-terminal proBNP in primary care patients with suspected heart failure. J Card Fail. 2005;11 (5 Suppl): S15–20.
  80. Nielsen OW, Rasmussen V, Christensen NJ, Hansen JF. Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability. Scand J Clin Lab Invest. 2004;64 (7):619–628.
  81. Porapakkham P, Porapakkham P, Zimmet H et al. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med. 2010;170 (6):507–514.
  82. Lang RM, Bierig M, Devereux RB et al. American Society of Echocardiography 's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7 (2):79–108.
  83. Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (1):112–115.
  84. Lang RM, Badano LP, Tsang W et al. EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography. Eur Heart J Cardiovasc Imaging. 2012;13 (1):1–46.
  85. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10 (2):165–193.
  86. Nagueh S, Middleton K, Kopelen H et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997;30 (6):1527–1533.
  87. Schwitter J, Arai AE. Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance. Eur Heart J. 2011;32 (7):799–809.
  88. Kilner PJ, Geva T, Kaemmerer H et al. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology. Eur Heart J. 2010;31 (7):794–805.
  89. Luchinger R , Schwitter J, Bruder O. Safety of CMR . In: Schwitter J, ed. CMR Update 2012. 2nd ed. Lausanne; p. 31–51. ISBN: 9783033016743.
  90. Bruder O, Schneider S, Nothnagel D et al. Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients. from the EuroCMR Registry. JACC Cardiovasc Imaging. 2011;4 (11):1171–1176.
  91. Cooper LT, Baughman KL, Feldman AM et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2007;28 (24):3076–3093.
  92. Arena R , Myers J, Guazzi M. Cardiopulmonary exercise testing is a core assessment for patients with heart failure. Congest Heart Fail. 2011;17 (3):115–119.
  93. Wedel H, McMurray JJ, Lindberg M et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009;11 (3):281–291.
  94. Allen LA, Felker GM, Pocock S et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11 (2):170–177.
  95. Jackson CE, Solomon SD, Gerstein HC et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;374 (9689):543–550.
  96. Felker GM, Allen LA, Pocock SJ et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007;50 (1):40–47.
  97. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27 (1):65–75.
  98. Komajda M, Carson PE, Hetzel S et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4 (1):27–35.
  99. Ketchum ES, Levy WC. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011;54 (2):86–96.
  100. Мареев В. Ю. Фармакоэкономическая оценка использования иАПФ в амбулаторном лечении больных сердечной недостаточностью (ФАСОН). Журнал Сердечная Недостаточность. 2002;3 (1):38–39.
  101. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Dallas, Tex; American Heart Association; 2005.
  102. Ho KK, Anderson KM, Kannel WB et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88 (1):107–115.
  103. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364 (9438):937–952.
  104. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med. 2001;249 (3):253–261.
  105. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Даниелян М. О. Первые результаты национального эпидемиологического исследования – эпидемиологическое обследование больных ХСН в реальной клинической практике (по обращаемости) – ЭПОХА–О–ХСН. Журнал Сердечная Недостаточность. 2003;4 (3):116–121.
  106. Kannel WB Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275 (24):1571–1576.
  107. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213 (7):1143–1152.
  108. Kostis JB, Davis BR , Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278 (3):212–216.
  109. Baker DW. Prevention of heart failure. J Card Fail. 2002;8 (5):333–346.
  110. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363 (9426):2022–2031.
  111. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42 (6):1206–1252.
  112. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358 (9290):1305–1315.
  113. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288 (23):2981–2997.
  114. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359 (12):1225–1237.
  115. Beckett NS, Peters R , Fletchers AE et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med. 2008;358 (18):1887–1898.
  116. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351 (9118):1755–1762.
  117. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317 (7160):703–713.
  118. PROGRESS Collaborative Group. Randomized trial of a perin-dopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358 (9287):1033–1041.
  119. Izzo JL Jr, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am. 2004;88 (5):1257–1271.
  120. Национальные рекомендации по профилактике, диагностике и лечению артериальной гипертонии (Рекомендации разработаны экспертами Всероссийского научного общества кардиологов в 2001 году и утверждены на Российском национальном конгрессе кардиологов 11 октября 2001 г., второй пересмотр Рекомендаций осуществлен в 2004 г.) http:www.cardiosite.ru/medical/recom-artgip.asp.
  121. Чазова И. Е., Бойцов С. А., Небиеридзе Д. В. и др. Диагностика и лечение артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2008;7 (6) Приложение 2.
  122. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362 (9386):782–788.
  123. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342 (3):145–153.
  124. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
  125. Yusuf S, Teo K, Anderson C et al. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372 (9644):1174–1183.
  126. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359 (23):2456–2467.
  127. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304 (14):801–807.
  128. Chadda K, Goldstein S, Byington R , Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73 (3):503–510.
  129. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992;327 (10):669–677.
  130. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet. 1994;343 (8906):1115–1122.
  131. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345 (8951):669–685.
  132. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349 (20):1893–1906.
  133. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348 (14):1309–1321.
  134. Vantrimpont P, Rouleau JL, Wun CC et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997;29 (2):229–236.
  135. Jones CG, Cleland JG. Meeting report: the LIDO, HOPE, MOXCON and WASH studies: Heart Outcomes Prevention Evaluation. The Warfarin / Aspirin Study of Heart Failure. Eur J Heart Fail. 1999;1 (4):425–431.
  136. Massie B. Final results jf the warfarin and antiplatelet trial in chronic heart failure (WATCH): a randomized comparison of warfarin, aspirin and clopidogrel. J Card Fail. 2004;10 (2):101–112.
  137. Kjekshus J, Pedersen TR, Olsson AG et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3(4):249–254.
  138. Lewis SJ, Moye LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129 (9):681–689.
  139. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339 (19):1349–1357.
  140. Диагностика и лечение стабильной стенокардии. Российские рекомендации (Разработаны Комитетом экспертов Всероссийского научного общества кардиологов). Доступно на: http://www.cardiosite.ru/medical/recom-stabsten.asp
  141. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза (Разработаны Комитетом экспертов Всероссийского научного общества кардиологов). Доступно на:http://www.cardiosite.ru/medical/recom-lipid.asp
  142. Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Доступно на: http://www.cardiosite.ru/medical/recom-lipid. asp
  143. Levy D, Larson MG, Vasan RS et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275 (20):1557–1562.
  144. Мареев В.Ю., Беленков Ю.Н. Хроническая сердечная недостаточность и инсулиннезависимый сахарный диабет: случайная связь или закономерность? Тер. Архив. 2003;75 (10):5–10.
  145. Ильина А.В., Мареев В.Ю., Герасимова В.В. и соавт. Эффективность терапии иАПФ фозиноприлом больных ХСН в сочетании с сахарным диабетом 2 типа (по материалам исследования ФАСОН). Журнал Сердечная Недостаточность. 2005;6 (5):181–185.
  146. Krumholz HM, Chen YT, Wang Y et al. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139 (1 Pt 1):72–77.
  147. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77 (11):1017–1020.
  148. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329 (20):1456–1462.
  149. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO – HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355 (9200):253–259.
  150. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345 (12):861–869.
  151. Berl T, Hunsicker LG, Lewis JB et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138 (7):542–549.
  152. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352 (9131):854–865.
  153. Eurich DT, Majumdar SR , McAlister FA et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28 (10):2345–2351.
  154. McAlister FA, Eurich DT, Majumdar SR , Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008;10 (7):703–708.
  155. Лапина Ю.В., Нарусов О.Ю., Мареев В.Ю. и др. Рациональная Эффективная Многокомпонентная терапия в БОрьбе с Сахарным Диабетом у больных ХСН (РЭМБО–СД ХСН) Хроническая сердечная недостаточность как фактор риска развития инсулинорезистентности и нарушений углеводного обмена. Журнал Сердечная Недостаточность. 2007;8 (4):164–170.
  156. Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370 (9590):829–840.
  157. Barzilay JI, Pressel S, Davis BR , et al. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: a report from the ALLHAT trial. ALLHAT Collaborative Research Group. Am J Hypertens. 2004;17 (5, part 2 of 2):1A.
  158. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339 (8):489–497.
  159. Heinemann L, Heise T, Ampudia J et al. Four week administration of an ACE inhibitor and a cardioselective β-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J Clin Invest. 1995;25 (8):595–600.
  160. Giugliano D, Acampora R , Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized controlled trial. Ann Intern Med. 1997;126 (12):955–959.
  161. Torp-Pedersen C, Metra M, Charlesworth A et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93 (8):968–973.
  162. Bakris GL, Fonseca V, Katholi RE et al. for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292 (18):2227–2236.
  163. Bonow RO, Carabello B, de Leon AC Jr et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation. 1998;98 (18):1949–1984.
  164. Leon MB, Smith CR , Mack M et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363 (17):1597–607.
  165. Smith CR , Leon MB, Mack MJ et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011 Jun 9;364 (23):2187–2198.
  166. Three-Year Outcomes after Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients with Severe Aortic Stenosis. Avaliable at: http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_450086.pdf
  167. Bach DS, Bolling SF. Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. Am J Cardiol. 1996;78 (8):966–969.
  168. Беленков Ю.Н. Б Мареев В.Ю. Принципы рационального лечения сердечной недостаточности. – М.: «Медиа Медика», 2000. –266 с.
  169. Greenberg B, Massie B, Bristow JD et al. Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial. Circulation. 1988;78 (1):92–103.
  170. Scognamiglio R , Rahimtoola SH, Fasoli G et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994;331 (11):689–694.
  171. Мареев В.Ю., Даниелян М.О. Недостаточность митрального клапана в терапевтической клинике. Русский медицинский журнал. 1999;7 (15):706–722.
  172. Feldman T, Foster E, Glower DD et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364 (15):1395–1406.
  173. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347 (5):358–359.
  174. Мареев В.Ю. Основные достижения в области понимания, диагностики и лечения ХСН в 2003 г. (часть 1). Журнал Сердечная Недостаточность. 2004;5 (1):25–31.
  175. Anker SD, Pomkowski P, Varney S. Wasting as independent risk factor of survival in chronic heart failure. Lancet. 1997;349 (9058):1050–1053.
  176. Anker SD, Coats AJ. Cachexia in heart failure is bad for you. Eur Heart J. 1998;19 (2):191–193.
  177. Paterna S, Gaspare P, Fasullo S et al. Normal-sodium diet compared with low sodium diet in compensated congestive heart failure. Clin Sci (Lond). 2008;114 (3):221–230.
  178. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90 (4):464–470.
  179. Von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002;85 (1):173–183.
  180. Cicoira M et al. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003;9 (3):219–226.
  181. Pasini E, Aquilani R , Gheorghiade M, Dioguardi FS. Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. Ital Heart J. 2003;4 (4):232–235.
  182. Heymsfield SB, Casper K. Congestive heart failure: clinical management by use of continuos nasoenteric feeding. Am J Clin Nutr. 1989;50 (3):539–544.
  183. Paccagnella A, Cali MA, Caenaro G et al. Cardiac cachexia: preoperative and postoperative nutrition management. J Parenter Enteral Nutr. 1994;18 (5):409–416.
  184. Шестопалов А.Е., Матраева Ю.С., Дьяков А.Ю. и др. Нутритивная поддержка и коррекция метаболических нарушений у больных с ишемической болезнью сердца и дефицитом тощей массы тела при хирургической реваскуляризации миокарда. Журнал Сердечная Недостаточность. 2001;2 (3):108–112.
  185. Арутюнов Г.П., Костюкевич О.И. Питание больных с хронической сердечной недостаточностью, проблемы нутритивной поддержки, решенные и нерешенные аспекты. Журнал Сердечная Недостаточность. 2002;3 (5):245–248.
  186. Walsh CR , Larson MG, Evans JC et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2002;136 (3):181–191.
  187. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 2001;285 (15):1971–1977.
  188. Осипова И.В., Ефремушкин Г.Г., Березенко Е.А. Длительные физические тренировки в комплексном лечении пожилых больных с хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2002;3 (5):218–221.
  189. Арутюнов Г.П. Вопросы немедикаментозного лечения пациентов, страдающих сердечной недостаточностью. Журнал Сердечная Недостаточность. 2001;2 (1):35–36.
  190. Осипова И.В. «Свободный выбор нагрузки» физических тренировок – эффективный метод лечения хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2001;2 (4):176–180.
  191. Exercise Standards. A statement for health professionals from the American Heart Association. Special Report. Circulation. 1990;82 (6):2291–2292.
  192. Gibbons RJ, Balady GJ, Beasley JW et al. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation. 1997;96 (1):345–354.
  193. Аронов Д.М. Кардиологическая реабилитация на рубеже веков. Сердце. 2002;1 (3):123–125.
  194. Feldman AM, Silver MA, Francis GS et al. Treating heart failure with enhanced external counterpulsation: design of the Procpective Evaluation of EECP in Congestive Heart Failure (PEECH) trial. J Card Fail. 2005;11 (3):240–245.
  195. Soran O, Fleishman B, Demarco T et al. Enhanced external counterpulsation in patients with heart failure: A multicenter feasibility study. Congest Heart Fail 2002;8 (4):204–227.
  196. Малахов В.В., Гарбусенко С.А., Сергиенко И.В. и соавт. Метод наружной контрпульсации в лечении больных сердечной недостаточностью. Кардиологический вестник. 2008;3 (15):22–27.
  197. Cowie MR , Mosterd A, Wood DA et al. The epidemiology of heart failure. Eur Heart J. 1997;18 (2):208–225.
  198. Spencer FA, Meyer TE, Goldberg RJ. Twenty year trends (1975–1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction. J Am Coll Cardiol. 1999;34 (5):1378–1387.
  199. Khand A, Gemmel I, Clark AL, Cleland JGF. Is the prognosis of heart failure improving? J Am Coll Cardiol. 2000;36 (7):2284–2286.
  200. Jong P, Vowinckel E, Liu PP et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162 (15):1689–1694.
  201. Garg R , Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA. 1995;273 (18):1450–1456.
  202. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Медикаментозные пути улучшения прогноза больных с хронической сердечной недочстаточностью. – М.: Инсайт, 1997. – 77с.
  203. NSAIDs and heart failure. Prescrire Int. 2001;10 (56):182–183.
  204. Shekelle PG, Rich MW, Morton SC. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41 (9):1529–1538.
  205. Keyhan G, Chen S, Pilote L. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail. 2007;9 (6-7):594–601.
  206. Bank AJ, Kubo SH, Rector TS et al. Local forearm vasodilation with intra-arterial administration of enalaprilat in humans. Clin Pharmacol Ther. 1991;50 (3):314–321.
  207. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Применение диклофенака и целебрекса у пациентов с артериальной гипертонией и болями в нижней части спины на фоне гипотензивной терапии аккупро или норваском (исследование ДОЦЕНТ). Журнал Сердечная Недостаточность. 2005;6 (33):204–208.
  208. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992;20 (7):1549–1555.
  209. Мареев В.Ю. Взаимодействие лекарственных средств при лечении больных с сердечно-сосудистыми заболеваниями. Ингибиторы АПФ и аспирин. Есть ли повод для тревоги? Сердце. 2002;1 (4):161–168.
  210. Al Khadra AS, Salem DN, Rand WM et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31 (2):419–425.
  211. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79 (2):115–119.
  212. Kindsvater S, Leclerc K, Ward J. Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Am J Cardiol. 2003;91 (11):1350–1352.
  213. Spaulding C, Charbonnier B, Cohen-Solal A et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation. 1998;98 (8):757–765.
  214. Лопатин Ю.М. Совместное применение аспирина и ингибиторов АПФ при ХСН: позиция «За». Журнал Сердечная Недостаточность. 2003;4 (19):149–152.
  215. Мареев В.Ю. Аспирин при хронической сердечной недостаточности. Взаимодействие аспирина с основными средствами лечения декомпенсации. Журнал Сердечная Недостаточность. 2003;4 (19):153–157.
  216. Teo KK, Yusuf S, Pfeffer M et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002;360 (9339):1037–1043.
  217. Harjai KJ, Solis S, Prasad A, Loupe J. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. Int J Cardiol. 2003;88 (2–3):207–214.
  218. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324 (7329):71–86.
  219. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med. 1992;327 (10):685–691.
  220. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med. 1991;325 (5):293–302.
Mareev V. Yu., Ageev F. T., Arutyunov G. P. et al. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision). Approved at the SEHF Congress on December 7, 2012, at the SEHF Board of Directors meeting on March 31, 2013, and at the RSC Congress on September 25, 2013. Russian Heart Failure Journal. 2013;14 (7):379-472

To access this material please log in or register

Register Authorize
Ru En